Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of respiratory events in Type 2 diabetics

admin by admin
February 17, 2023
in News


1. In this retrospective cohort study, patients with Type 2 Diabetes (T2D) using sodium-glucose cotransporter 2 inhibitors (SGLT2is) were found to have a lower incidence of adverse respiratory events than patients using dipeptidyl peptidase-4 inhibitors (DPP4is).

Evidence Rating Level: 2 (Good)

Type 2 Diabetes (T2D) shares a similar pathophysiological background with respiratory disease. Specifically, glucose levels of the airway surface liquid (ASL) influence respiratory dysfunction; low glucose levels in the ASL help prevent pulmonary infections and the exacerbation of respiratory diseases. Antidiabetic drugs reduce glucose levels, and accumulating evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2is) may offer greater benefit with respect to respiratory outcomes. SGLT2is have been found to reduce the risk of respiratory disorders, pneumonia, and respiratory failure versus dipeptidyl peptidase-4 inhibitors (DPP4is). This retrospective cohort study aimed to determine whether the use of SGLT2is is associated with the risk of adverse respiratory events among patients with T2D compared to DPP4is. Data was collected using the Health Insurance Review and Assessment Service (HIRA) database of South Korea. Patients who were newly prescribed an SGLT2i or DPP4i between January 2016 and December 2020 were identified and included in the study. The primary outcome studied was respiratory events, defined as a composite endpoint including acute pulmonary edema, ARDS, pneumonia, and respiratory failure. In total, after propensity score matching, 205,534 patients were included in each treatment group. With respect to the primary outcome, SGLT2i users displayed a lower incidence of adverse respiratory events when compared to DPP4i users (incidence rate 4.54 versus 7.54 events per 1000 person-years; rate difference: − 3.00, 95% CI − 3.44 to − 2.55). SGLT2i users had lower risks of the composite respiratory endpoint (HR 0.60, 95% CI 0.55 to 0.64), as well as acute pulmonary edema, pneumonia, and respiratory failure. The same trends persisted even after subgroup and stratified analyses, in each age, sex, history of asthma, history of COPD, history of CVD, history of CKD, and history of baseline insulin use subgroup. Overall, the findings from this study suggest that among patients with T2D, SGLT2i users had a 40% lower risk of adverse respiratory events than DPP4i users. A major limitation of this study is the homogenous patient population, as the study was completed in South Korea, which may affect the generalizability of the data. However, this study is an important addition to the growing body of evidence surrounding T2D and respiratory events and will guide further research.

Click to read the study in BMC Medicine

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.



Source link

Advertisement Banner
Previous Post

Minnesota journalist uncovers lawsuits Mayo Clinic filed against patients

Next Post

All Three Legs of the Obamacare Stool Are Working Well – Part 2 – The Health Care Blog

Related Posts

News

QA AND Advocacy: How Pediatricians Can Improve LGBTQ Mental Healthcare

October 3, 2023
News

Simplified Assessment Tool Predicts Psoriasis Severity

October 2, 2023
News

Glucagon-like peptide-1 receptor agonists exhibit weight loss effects in non-diabetic patients with obesity

October 1, 2023
News

#VisualAbstract: Complete or Culprit-Only Percutaneous Coronary Intervention in Older Patients with Myocardial Infarction

September 30, 2023
News

Causal Impact of Circulating Proteome on Osteoarthritis Traits

September 29, 2023
News

Surprising Phacodonesis Risk in Pseudoexfoliation Patients During Cataract Surgery

September 28, 2023
Next Post

All Three Legs of the Obamacare Stool Are Working Well – Part 2 – The Health Care Blog

Recommended

Vitiligo Responding and Refractory Alopecia Areata During the Monotherapy With Tofacitinib

8 months ago

UnitedHealth, Humana see unexpected rise in Medicare Advantage costs

4 months ago

Patient-supporter training improved patient confidence in managing diabetes

9 months ago

AHCJ mentorship program expanding, seeks participants

4 weeks ago

Good, bad or ugly? – The Health Care Blog

2 months ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.